Skip to content
TrialScanner

NCT04082364

Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer

Phase 2/Phase 3CompletedMGNXLead

Registry record

Lead sponsor
MacroGenics
Conditions
Gastric Cancer; Gastroesophageal Junction Cancer; HER2-positive Gastric Cancer
Primary completion
Jan 15, 2024Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04082364 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04082364: Combination Margetuximab... | TrialScanner